Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma

Lymphoma

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol

Br J Haematol

Mikhaeel NG, Bouziana S, Northend M, Brady JL, Sanderson R, Sivabalasingham S, Springell D, Roddie C, Bourlon C, Farias MC, Davila AM, Benjamin R, Patten PEM, Kumar E, Yallop D, Hwang A, Kamat S, Ntentas G, Kuhnl A

doi: 10.1111/bjh.70653

Lymphoma

Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis

Lancet Haematol

Spanjaart AM, Bakker M, de Vries R, Hutten BA, van Nieuwenhuijzen N, Minnema MC, Kuipers MT, Kersten MJ

doi: 10.1016/S2352-3026(26)00045-1

Lymphoma

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial

Ann Oncol

Michot JM, Bologna S, Bastie JN, Borght TV, Brière J, Ribrag V, Bommier C, Peyrade F, Lebras L, Damaj G, Coso D, Sibon D, Bonnet C, Morschhauser F, Ghesquières H, Fruchart C, Soussain C, Becker S, Olivier P, Julian A, Molina T, Haioun C, Tilly H

doi: 10.1016/j.annonc.2025.11.006

Lymphoma

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy

J Clin Oncol

Stepan L, Ansari S, Abramson JS, Okal A, Dell'Aringa J, Thompson EG, Crotta A, Chow VA, Kamdar M, Solomon SR, Johnston PB, Glass B, Mutsaers P, Arnason J, Mielke S, Shadman M, Hernandez-Ilizaliturri F, Izutsu K, Bachanova V, Ibrahimi S, Chabon JJ, Kurtz DM, Alizadeh AA, Peiser L

doi: 10.1200/JCO-25-03051

Lymphoma

Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017-2024)

Leuk Lymphoma

Phillips T, Zhou Z, Gutierrez C, Shao A, Boyd M, Noshad S, Hohlbauch A, Liu N, Repetny K, Fanale M, Mitchell B, Davis EA, Gennarelli R, Burke JM

doi: 10.1080/10428194.2025.2604300

Lymphoma

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial

J Clin Oncol

Matasar M, Li Z, Vassilakopoulos TP, Sancho JM, Viardot A, McMillan A, Dal MS, Pereira J, Kim JS, Qiu L, Batlevi CL, Ibrahim R, Hernandez J, McCall B, Jiang Y, Yan M, Harris W, Musick L, Haioun C

doi: 10.1200/JCO-25-02849

Lymphoma

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma

J Clin Oncol

Wang S, Nijland M, Strobbe L, Oosterveld M, Boersma R, Koene H, Klerk C, de Jongh E, Koster A, Pruijt H, van der Poel M, van Werkhoven E, Zanders H, Dinmohamed A, Pegtel M, Meek S, Stowell SL, Warinske H, Alizadeh AA, Kurtz DM, Chamuleau MED

doi: 10.1200/JCO-25-01712

Lymphoma

CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis

Am J Hematol

Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikarn K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF

doi: 10.1002/ajh.70033

Lymphoma

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence

Blood Cancer J

Perrone S, Molica M, Giannarelli D, Pacitto G, Ferrero S

doi: 10.1038/s41408-026-01552-5

Related content

Response-adapted chimeric antigen receptor T cell (CAR-T)-sparing consolidation radiotherapy in high-risk large B-cell lymphoma (LBCL): Results of the prospective RESTART protocol

Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy

Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017-2024)

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial

Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma

CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis

Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence